Tasidotin

Drug Profile

Tasidotin

Alternative Names: BSF 223651; ILX 651; LU 223651; SYN-D; Synthadotin; Tasidotin HCl; Tasidotin hydrochloride

Latest Information Update: 05 Aug 2011

Price : $50

At a glance

  • Originator Abbott Bioresearch Corporation
  • Developer Genzyme Oncology; Sanofi Oncology
  • Class Antineoplastics; Oligopeptides; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Phase I Malignant melanoma
  • Preclinical Solid tumours
  • Discontinued Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 28 Apr 2011 Phase-I clinical trials in Malignant melanoma in USA (PO)
  • 16 Mar 2010 Preclinical development is ongoing in USA
  • 06 May 2009 Genzyme Corporation and Ergomed agree to co-develop orally administered Tasidotin for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top